Firsekibart clinical trials
How each study uses firsekibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the firsekibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Firsekibart
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Tongji Hospital (2) · Chinese SLE Treatment And Research Group (1) · Children's Hospital of Fudan University (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test firsekibart, phase 3 first.
- Sep 2027Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki DiseasePhase 2/3 · Children's Hospital of Fudan University
- Dec 2026A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot applicable · Tongji Hospital
- Apr 2027Efficacy and Safety of Firsekibart in the Treatment of Systemic SclerosisNot applicable · Tongji Hospital
Studies
Open first, then newest update. How each study uses firsekibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki DiseaseNot yet recruitingPhase 2/3Children's Hospital of Fudan UniversityNCT07686770Written as Firsekibart
- 24-Week Recurrence Rate of Gout Following Firsekibart TreatmentNot yet recruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07625514Written as Firsekibart
- Efficacy and Safety of Firsekibart in the Treatment of Systemic SclerosisNot yet recruitingNot applicableTongji HospitalNCT07502105Written as Firsekibart injection
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNot applicableTongji HospitalNCT07535840Written as Firsekibart + Tislelizumab + Lenvatinib
- Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus ErythematosusActive, not recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07381465Written as Firsekibart
Codes
What other systems call firsekibart · ClinicalTrials.gg INT015354
- UNII (FDA) 6ZU8B6H4KTFIRSEKIBARTOne source FDA
- NCI Thesaurus C215737FirsekibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6ZU8B6H4KT | FIRSEKIBART | One source FDA |
| NCI Thesaurus | C215737 | Firsekibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.